Skip to main content

Table 4 Primary, Secondary Outcome Variables (Intent-to-Treat Analysis)

From: Review of Desloratadine Data Using the ARIA Guidelines

 

5-mg DL

Placebo

 

Baseline LS (m ± SEM)

LS

(m ± SEM)

Baseline LS (m ± SEM)

LS

(m ± SEM)

P

AM/PM T5SS reflective (days 1-29)

9.63 ± 0.13

-3.76 ± 0.22

9.55 ± 0.21

-2.87 ± 0.21

<0.001

RQLQ total score

 

day 29

3.30 ± 10.08

-1.35 ± 0.10

3.15 ± 0.08

-0.95 ± 0.10

<0.001

day 85

 

-1.66 ± 0.11

 

-1.39 ± 0.12

0.023

AM/PM T5SS reflective

 

-4.50 ± 0.23

 

-3.61 ± 0.23

<0.001

(days 1-85)

 

AM/PM T5SS instantaneous

 

days 1-29

9.35 ± 0.15

-3.41 ± 0.22

9.23 ± 0.14

-2.52 ± 0.22

<0.001

days 1-85

 

-4.11 ± 0.24

 

-3.22 ± 0.23

<0.001

AM/PM rhinorrhea reflective

 

days 1-29

2.10 ± 0.04

-0.81 ± 0.05

2.08 ± 0.04

-0.62 ± 0.05

<0.001

days 1-85

 

-0.98 ± 0.05

 

-0.77 ± 0.05

<0.001

AM/PM nasal congestion reflective

 

days 1-29

2.13 ± 0.04

-0.69 ± 0.05

2.1 ± 0.04

-0.53 ± 0.05

0.002

days 1-85

 

-0.87 ± 0.05

 

-0.70 ± 0.05

0.002

AM/PM sneezing reflective

 

days 1-29

1.88 ± 0.04

-0.83 ± 0.05

1.84 ± 0.04

-0.62 ± 0.05

<0.001

days 1-85

 

-0.96 ± 0.05

 

-0.76 ± 0.05

<0.001

AM/PM nasal itching reflective

 

days 1-29

1.89 ± 0.04

-0.77 ± 0.05

1.88 ± 0.04

-0.58 ± 0.05

<0.001

days 1-85

 

-0.91 ± 0.05

 

-0.65 ± 0.05

0.002

AM/PM eye itching reflective

 

days 1-29

1.62 ± 0.05

-0.67 ± 0.05

1.64 ± 0.05

-0.52 ± 0.05

0.006

days 1-85

 

-0.78 ± 0.05

 

-0.65 ± 0.05

0.016

Sleep interference

 

2-29 days

1.58 ± 0.05

-0.54 ± 0.06

1.59 ± 0.05

-0.42 ± 0.05

0.022

2-85 days

 

-0.65 ± 0.06

 

-0.52 ± 0.06

0.023

Activity interference

 

1-29 days

1.89 ± 0.04

−0.69 ± 0.05

1.89 ± 0.04

-0.46 ± 0.05

<0.001

1-85 days

 

-0.82 ± -0.06

 

-0.60 ± -0.06

<0.001

Symptom severity reflective (VAS)

 

days 2-29

61.2 ± 1.20

-19.7 ± 1.52

59.80 ± 1.19

-12.7 ± 1.50

<0.001

days 2-85

 

-25.7 ± 1.64

 

-18.0 ± 1.61

<0.001

Patient's evaluation of response (day 85)

NA

2.70 ± 0.10

NA

3.11 ± 0.10

<0.001

  1. LS, least significant. means, SEM (SE of the LS means) are obtained from an ANOVA model with treatment and site effects. NA, not applicable.
Back to article page

World Allergy Organization Journal

ISSN: 1939-4551

Contact us